Clinical trial
A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
NCT06665646 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 14, 2025
- Completion date
- November 30, 2027
- Enrollment
- 40 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.